Click for best price
Cardiovascular Drugs Market Size, Share 2023
| Market size in 2022 |
US$ 6189 million
|
Forecast Market size by 2029 |
US$ 6525.7 million
|
| Growth Rate |
CAGR of 0.8% |
Number of Pages |
78 Pages |
Cardiovascular Drugs and Therapy is a bimonthly peer-reviewed medical journal covering pharmacotherapy as it relates to cardiology. It was established in 1987 and is published by Springer Science+Business Media on behalf of the International Society of Cardiovascular Pharmacotherapy, of which it is the official journal. The editors-in-chief are Willem J. Remme (Carol Davila University of Medicine and Pharmacy) and Robert S. Rosenson (Icahn School of Medicine at Mount Sinai).
This report aims to provide a comprehensive presentation of the global market for Cardiovascular Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cardiovascular Drugs. This report contains market size and forecasts of Cardiovascular Drugs in global, including the following market information:
Global Cardiovascular Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Cardiovascular Drugs Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Cardiovascular Drugs companies in 2022 (%)
The global Cardiovascular Drugs market was valued at US$ 6189 million in 2022 and is projected to reach US$ 6525.7 million by 2029, at a CAGR of 0.8% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Geographically, North America captured lion?s share of global cardiovascular drugs market in 2016. However increasing adoption of generics in the U.S. is key concern area among key players. Asia Pacific market is projected to gain market share during the forecast period and is likely to be key revenue generator in the coming years. Initiatives by local governments to attain self-sufficiency in manufacturing pharmaceuticals and incentives for generic production in countries such as Brazil, South Africa, Saudi Arabia, etc. is likely to boost market growth in Latin America and Middle East & Africa.
We surveyed the Cardiovascular Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Cardiovascular Drugs Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Cardiovascular Drugs Market Segment Percentages, by Type, 2022 (%)
Renin-Angiotensin System Blockers
Beta Blockers
Diuretics
Anti-Clotting Agents
Antihyperlipidemic
Global Cardiovascular Drugs Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Cardiovascular Drugs Market Segment Percentages, by Application, 2022 (%)
Hypertension
Hyperlipidemia
Global Cardiovascular Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Cardiovascular Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Cardiovascular Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Cardiovascular Drugs revenues share in global market, 2022 (%)
Key companies Cardiovascular Drugs sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Cardiovascular Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Amgen
AstraZeneca
Bayer
Bristol Myers Squibb and Pfizer
Daiichi Sankyo
Johnson & Johnson
Merck & Co.
Novartis
Pfizer
Portola
Sanofi
Outline of Major Chapters:
Chapter 1: Introduces the definition of Cardiovascular Drugs, market overview.
Chapter 2: Global Cardiovascular Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Cardiovascular Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Cardiovascular Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Cardiovascular Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Cardiovascular Drugs Market, Global Outlook and Forecast 2023-2029 |
| Market size in 2022 |
US$ 6189 million
|
| Forecast Market size by 2029 |
US$ 6525.7 million
|
| Growth Rate |
CAGR of 0.8% |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
78 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Cardiovascular Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Cardiovascular Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Cardiovascular Drugs Overall Market Size
2.1 Global Cardiovascular Drugs Market Size: 2022 VS 2029
2.2 Global Cardiovascular Drugs Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Cardiovascular Drugs Sales: 2018-2029
3 Company Landscape
3.1 Top Cardiovascular Drugs Players in Global Market
3.2 Top Global Cardiovascular Drugs Companies Ranked by Revenue
3.3 Global Cardiovascular Drugs Revenue by Companies
3.4 Global Cardiovascular Drugs Sales by Companies
3.5 Global Cardiovascular Drugs Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Cardiovascular Drugs Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Cardiovascular Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Cardiovascular Drugs Players in Global Market
3.8.1 List of Global Tier 1 Cardiovascular Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Cardiovascular Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Cardiovascular Drugs Market Size Markets, 2022 & 2029
4.1.2 Renin-Angiotensin System Blockers
4.1.3 Beta Blockers
4.1.4 Diuretics
4.1.5 Anti-Clotting Agents
4.1.6 Antihyperlipidemic
4.2 By Type - Global Cardiovascular Drugs Revenue & Forecasts
4.2.1 By Type - Global Cardiovascular Drugs Revenue, 2018-2023
4.2.2 By Type - Global Cardiovascular Drugs Revenue, 2024-2029
4.2.3 By Type - Global Cardiovascular Drugs Revenue Market Share, 2018-2029
4.3 By Type - Global Cardiovascular Drugs Sales & Forecasts
4.3.1 By Type - Global Cardiovascular Drugs Sales, 2018-2023
4.3.2 By Type - Global Cardiovascular Drugs Sales, 2024-2029
4.3.3 By Type - Global Cardiovascular Drugs Sales Market Share, 2018-2029
4.4 By Type - Global Cardiovascular Drugs Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Cardiovascular Drugs Market Size, 2022 & 2029
5.1.2 Hypertension
5.1.3 Hyperlipidemia
5.2 By Application - Global Cardiovascular Drugs Revenue & Forecasts
5.2.1 By Application - Global Cardiovascular Drugs Revenue, 2018-2023
5.2.2 By Application - Global Cardiovascular Drugs Revenue, 2024-2029
5.2.3 By Application - Global Cardiovascular Drugs Revenue Market Share, 2018-2029
5.3 By Application - Global Cardiovascular Drugs Sales & Forecasts
5.3.1 By Application - Global Cardiovascular Drugs Sales, 2018-2023
5.3.2 By Application - Global Cardiovascular Drugs Sales, 2024-2029
5.3.3 By Application - Global Cardiovascular Drugs Sales Market Share, 2018-2029
5.4 By Application - Global Cardiovascular Drugs Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region - Global Cardiovascular Drugs Market Size, 2022 & 2029
6.2 By Region - Global Cardiovascular Drugs Revenue & Forecasts
6.2.1 By Region - Global Cardiovascular Drugs Revenue, 2018-2023
6.2.2 By Region - Global Cardiovascular Drugs Revenue, 2024-2029
6.2.3 By Region - Global Cardiovascular Drugs Revenue Market Share, 2018-2029
6.3 By Region - Global Cardiovascular Drugs Sales & Forecasts
6.3.1 By Region - Global Cardiovascular Drugs Sales, 2018-2023
6.3.2 By Region - Global Cardiovascular Drugs Sales, 2024-2029
6.3.3 By Region - Global Cardiovascular Drugs Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country - North America Cardiovascular Drugs Revenue, 2018-2029
6.4.2 By Country - North America Cardiovascular Drugs Sales, 2018-2029
6.4.3 US Cardiovascular Drugs Market Size, 2018-2029
6.4.4 Canada Cardiovascular Drugs Market Size, 2018-2029
6.4.5 Mexico Cardiovascular Drugs Market Size, 2018-2029
6.5 Europe
6.5.1 By Country - Europe Cardiovascular Drugs Revenue, 2018-2029
6.5.2 By Country - Europe Cardiovascular Drugs Sales, 2018-2029
6.5.3 Germany Cardiovascular Drugs Market Size, 2018-2029
6.5.4 France Cardiovascular Drugs Market Size, 2018-2029
6.5.5 U.K. Cardiovascular Drugs Market Size, 2018-2029
6.5.6 Italy Cardiovascular Drugs Market Size, 2018-2029
6.5.7 Russia Cardiovascular Drugs Market Size, 2018-2029
6.5.8 Nordic Countries Cardiovascular Drugs Market Size, 2018-2029
6.5.9 Benelux Cardiovascular Drugs Market Size, 2018-2029
6.6 Asia
6.6.1 By Region - Asia Cardiovascular Drugs Revenue, 2018-2029
6.6.2 By Region - Asia Cardiovascular Drugs Sales, 2018-2029
6.6.3 China Cardiovascular Drugs Market Size, 2018-2029
6.6.4 Japan Cardiovascular Drugs Market Size, 2018-2029
6.6.5 South Korea Cardiovascular Drugs Market Size, 2018-2029
6.6.6 Southeast Asia Cardiovascular Drugs Market Size, 2018-2029
6.6.7 India Cardiovascular Drugs Market Size, 2018-2029
6.7 South America
6.7.1 By Country - South America Cardiovascular Drugs Revenue, 2018-2029
6.7.2 By Country - South America Cardiovascular Drugs Sales, 2018-2029
6.7.3 Brazil Cardiovascular Drugs Market Size, 2018-2029
6.7.4 Argentina Cardiovascular Drugs Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Cardiovascular Drugs Revenue, 2018-2029
6.8.2 By Country - Middle East & Africa Cardiovascular Drugs Sales, 2018-2029
6.8.3 Turkey Cardiovascular Drugs Market Size, 2018-2029
6.8.4 Israel Cardiovascular Drugs Market Size, 2018-2029
6.8.5 Saudi Arabia Cardiovascular Drugs Market Size, 2018-2029
6.8.6 UAE Cardiovascular Drugs Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Amgen
7.1.1 Amgen Company Summary
7.1.2 Amgen Business Overview
7.1.3 Amgen Cardiovascular Drugs Major Product Offerings
7.1.4 Amgen Cardiovascular Drugs Sales and Revenue in Global (2018-2023)
7.1.5 Amgen Key News & Latest Developments
7.2 AstraZeneca
7.2.1 AstraZeneca Company Summary
7.2.2 AstraZeneca Business Overview
7.2.3 AstraZeneca Cardiovascular Drugs Major Product Offerings
7.2.4 AstraZeneca Cardiovascular Drugs Sales and Revenue in Global (2018-2023)
7.2.5 AstraZeneca Key News & Latest Developments
7.3 Bayer
7.3.1 Bayer Company Summary
7.3.2 Bayer Business Overview
7.3.3 Bayer Cardiovascular Drugs Major Product Offerings
7.3.4 Bayer Cardiovascular Drugs Sales and Revenue in Global (2018-2023)
7.3.5 Bayer Key News & Latest Developments
7.4 Bristol Myers Squibb and Pfizer
7.4.1 Bristol Myers Squibb and Pfizer Company Summary
7.4.2 Bristol Myers Squibb and Pfizer Business Overview
7.4.3 Bristol Myers Squibb and Pfizer Cardiovascular Drugs Major Product Offerings
7.4.4 Bristol Myers Squibb and Pfizer Cardiovascular Drugs Sales and Revenue in Global (2018-2023)
7.4.5 Bristol Myers Squibb and Pfizer Key News & Latest Developments
7.5 Daiichi Sankyo
7.5.1 Daiichi Sankyo Company Summary
7.5.2 Daiichi Sankyo Business Overview
7.5.3 Daiichi Sankyo Cardiovascular Drugs Major Product Offerings
7.5.4 Daiichi Sankyo Cardiovascular Drugs Sales and Revenue in Global (2018-2023)
7.5.5 Daiichi Sankyo Key News & Latest Developments
7.6 Johnson & Johnson
7.6.1 Johnson & Johnson Company Summary
7.6.2 Johnson & Johnson Business Overview
7.6.3 Johnson & Johnson Cardiovascular Drugs Major Product Offerings
7.6.4 Johnson & Johnson Cardiovascular Drugs Sales and Revenue in Global (2018-2023)
7.6.5 Johnson & Johnson Key News & Latest Developments
7.7 Merck & Co.
7.7.1 Merck & Co. Company Summary
7.7.2 Merck & Co. Business Overview
7.7.3 Merck & Co. Cardiovascular Drugs Major Product Offerings
7.7.4 Merck & Co. Cardiovascular Drugs Sales and Revenue in Global (2018-2023)
7.7.5 Merck & Co. Key News & Latest Developments
7.8 Novartis
7.8.1 Novartis Company Summary
7.8.2 Novartis Business Overview
7.8.3 Novartis Cardiovascular Drugs Major Product Offerings
7.8.4 Novartis Cardiovascular Drugs Sales and Revenue in Global (2018-2023)
7.8.5 Novartis Key News & Latest Developments
7.9 Pfizer
7.9.1 Pfizer Company Summary
7.9.2 Pfizer Business Overview
7.9.3 Pfizer Cardiovascular Drugs Major Product Offerings
7.9.4 Pfizer Cardiovascular Drugs Sales and Revenue in Global (2018-2023)
7.9.5 Pfizer Key News & Latest Developments
7.10 Portola
7.10.1 Portola Company Summary
7.10.2 Portola Business Overview
7.10.3 Portola Cardiovascular Drugs Major Product Offerings
7.10.4 Portola Cardiovascular Drugs Sales and Revenue in Global (2018-2023)
7.10.5 Portola Key News & Latest Developments
7.11 Sanofi
7.11.1 Sanofi Company Summary
7.11.2 Sanofi Cardiovascular Drugs Business Overview
7.11.3 Sanofi Cardiovascular Drugs Major Product Offerings
7.11.4 Sanofi Cardiovascular Drugs Sales and Revenue in Global (2018-2023)
7.11.5 Sanofi Key News & Latest Developments
8 Global Cardiovascular Drugs Production Capacity, Analysis
8.1 Global Cardiovascular Drugs Production Capacity, 2018-2029
8.2 Cardiovascular Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Cardiovascular Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Cardiovascular Drugs Supply Chain Analysis
10.1 Cardiovascular Drugs Industry Value Chain
10.2 Cardiovascular Drugs Upstream Market
10.3 Cardiovascular Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Cardiovascular Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Cardiovascular Drugs in Global Market
Table 2. Top Cardiovascular Drugs Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Cardiovascular Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Cardiovascular Drugs Revenue Share by Companies, 2018-2023
Table 5. Global Cardiovascular Drugs Sales by Companies, (K Units), 2018-2023
Table 6. Global Cardiovascular Drugs Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Cardiovascular Drugs Price (2018-2023) & (USD/Unit)
Table 8. Global Manufacturers Cardiovascular Drugs Product Type
Table 9. List of Global Tier 1 Cardiovascular Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Cardiovascular Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Cardiovascular Drugs Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Cardiovascular Drugs Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Cardiovascular Drugs Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Cardiovascular Drugs Sales (K Units), 2018-2023
Table 15. By Type - Global Cardiovascular Drugs Sales (K Units), 2024-2029
Table 16. By Application ? Global Cardiovascular Drugs Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Cardiovascular Drugs Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Cardiovascular Drugs Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Cardiovascular Drugs Sales (K Units), 2018-2023
Table 20. By Application - Global Cardiovascular Drugs Sales (K Units), 2024-2029
Table 21. By Region ? Global Cardiovascular Drugs Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Cardiovascular Drugs Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Cardiovascular Drugs Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Cardiovascular Drugs Sales (K Units), 2018-2023
Table 25. By Region - Global Cardiovascular Drugs Sales (K Units), 2024-2029
Table 26. By Country - North America Cardiovascular Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Cardiovascular Drugs Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Cardiovascular Drugs Sales, (K Units), 2018-2023
Table 29. By Country - North America Cardiovascular Drugs Sales, (K Units), 2024-2029
Table 30. By Country - Europe Cardiovascular Drugs Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Cardiovascular Drugs Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Cardiovascular Drugs Sales, (K Units), 2018-2023
Table 33. By Country - Europe Cardiovascular Drugs Sales, (K Units), 2024-2029
Table 34. By Region - Asia Cardiovascular Drugs Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Cardiovascular Drugs Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Cardiovascular Drugs Sales, (K Units), 2018-2023
Table 37. By Region - Asia Cardiovascular Drugs Sales, (K Units), 2024-2029
Table 38. By Country - South America Cardiovascular Drugs Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Cardiovascular Drugs Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Cardiovascular Drugs Sales, (K Units), 2018-2023
Table 41. By Country - South America Cardiovascular Drugs Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa Cardiovascular Drugs Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Cardiovascular Drugs Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Cardiovascular Drugs Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Cardiovascular Drugs Sales, (K Units), 2024-2029
Table 46. Amgen Company Summary
Table 47. Amgen Cardiovascular Drugs Product Offerings
Table 48. Amgen Cardiovascular Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 49. Amgen Key News & Latest Developments
Table 50. AstraZeneca Company Summary
Table 51. AstraZeneca Cardiovascular Drugs Product Offerings
Table 52. AstraZeneca Cardiovascular Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 53. AstraZeneca Key News & Latest Developments
Table 54. Bayer Company Summary
Table 55. Bayer Cardiovascular Drugs Product Offerings
Table 56. Bayer Cardiovascular Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 57. Bayer Key News & Latest Developments
Table 58. Bristol Myers Squibb and Pfizer Company Summary
Table 59. Bristol Myers Squibb and Pfizer Cardiovascular Drugs Product Offerings
Table 60. Bristol Myers Squibb and Pfizer Cardiovascular Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 61. Bristol Myers Squibb and Pfizer Key News & Latest Developments
Table 62. Daiichi Sankyo Company Summary
Table 63. Daiichi Sankyo Cardiovascular Drugs Product Offerings
Table 64. Daiichi Sankyo Cardiovascular Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 65. Daiichi Sankyo Key News & Latest Developments
Table 66. Johnson & Johnson Company Summary
Table 67. Johnson & Johnson Cardiovascular Drugs Product Offerings
Table 68. Johnson & Johnson Cardiovascular Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 69. Johnson & Johnson Key News & Latest Developments
Table 70. Merck & Co. Company Summary
Table 71. Merck & Co. Cardiovascular Drugs Product Offerings
Table 72. Merck & Co. Cardiovascular Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 73. Merck & Co. Key News & Latest Developments
Table 74. Novartis Company Summary
Table 75. Novartis Cardiovascular Drugs Product Offerings
Table 76. Novartis Cardiovascular Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 77. Novartis Key News & Latest Developments
Table 78. Pfizer Company Summary
Table 79. Pfizer Cardiovascular Drugs Product Offerings
Table 80. Pfizer Cardiovascular Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 81. Pfizer Key News & Latest Developments
Table 82. Portola Company Summary
Table 83. Portola Cardiovascular Drugs Product Offerings
Table 84. Portola Cardiovascular Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 85. Portola Key News & Latest Developments
Table 86. Sanofi Company Summary
Table 87. Sanofi Cardiovascular Drugs Product Offerings
Table 88. Sanofi Cardiovascular Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 89. Sanofi Key News & Latest Developments
Table 90. Cardiovascular Drugs Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 91. Global Cardiovascular Drugs Capacity Market Share of Key Manufacturers, 2021-2023
Table 92. Global Cardiovascular Drugs Production by Region, 2018-2023 (K Units)
Table 93. Global Cardiovascular Drugs Production by Region, 2024-2029 (K Units)
Table 94. Cardiovascular Drugs Market Opportunities & Trends in Global Market
Table 95. Cardiovascular Drugs Market Drivers in Global Market
Table 96. Cardiovascular Drugs Market Restraints in Global Market
Table 97. Cardiovascular Drugs Raw Materials
Table 98. Cardiovascular Drugs Raw Materials Suppliers in Global Market
Table 99. Typical Cardiovascular Drugs Downstream
Table 100. Cardiovascular Drugs Downstream Clients in Global Market
Table 101. Cardiovascular Drugs Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Cardiovascular Drugs Segment by Type in 2022
Figure 2. Cardiovascular Drugs Segment by Application in 2022
Figure 3. Global Cardiovascular Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Cardiovascular Drugs Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Cardiovascular Drugs Revenue, 2018-2029 (US$, Mn)
Figure 7. Cardiovascular Drugs Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Cardiovascular Drugs Revenue in 2022
Figure 9. By Type - Global Cardiovascular Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Cardiovascular Drugs Revenue Market Share, 2018-2029
Figure 11. By Type - Global Cardiovascular Drugs Sales Market Share, 2018-2029
Figure 12. By Type - Global Cardiovascular Drugs Price (USD/Unit), 2018-2029
Figure 13. By Application - Global Cardiovascular Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Cardiovascular Drugs Revenue Market Share, 2018-2029
Figure 15. By Application - Global Cardiovascular Drugs Sales Market Share, 2018-2029
Figure 16. By Application - Global Cardiovascular Drugs Price (USD/Unit), 2018-2029
Figure 17. By Region - Global Cardiovascular Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Cardiovascular Drugs Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Cardiovascular Drugs Revenue Market Share, 2018-2029
Figure 20. By Region - Global Cardiovascular Drugs Sales Market Share, 2018-2029
Figure 21. By Country - North America Cardiovascular Drugs Revenue Market Share, 2018-2029
Figure 22. By Country - North America Cardiovascular Drugs Sales Market Share, 2018-2029
Figure 23. US Cardiovascular Drugs Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Cardiovascular Drugs Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Cardiovascular Drugs Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Cardiovascular Drugs Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Cardiovascular Drugs Sales Market Share, 2018-2029
Figure 28. Germany Cardiovascular Drugs Revenue, (US$, Mn), 2018-2029
Figure 29. France Cardiovascular Drugs Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Cardiovascular Drugs Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Cardiovascular Drugs Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Cardiovascular Drugs Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Cardiovascular Drugs Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Cardiovascular Drugs Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Cardiovascular Drugs Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Cardiovascular Drugs Sales Market Share, 2018-2029
Figure 37. China Cardiovascular Drugs Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Cardiovascular Drugs Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Cardiovascular Drugs Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Cardiovascular Drugs Revenue, (US$, Mn), 2018-2029
Figure 41. India Cardiovascular Drugs Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Cardiovascular Drugs Revenue Market Share, 2018-2029
Figure 43. By Country - South America Cardiovascular Drugs Sales Market Share, 2018-2029
Figure 44. Brazil Cardiovascular Drugs Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Cardiovascular Drugs Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Cardiovascular Drugs Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Cardiovascular Drugs Sales Market Share, 2018-2029
Figure 48. Turkey Cardiovascular Drugs Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Cardiovascular Drugs Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Cardiovascular Drugs Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Cardiovascular Drugs Revenue, (US$, Mn), 2018-2029
Figure 52. Global Cardiovascular Drugs Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production Cardiovascular Drugs by Region, 2022 VS 2029
Figure 54. Cardiovascular Drugs Industry Value Chain
Figure 55. Marketing Channels
